Primary Hyperoxaluria Treatment Market

Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).
Primary Hyperoxaluria Treatment Market contains market size and forecasts of Primary Hyperoxaluria Treatment in global, including the following market information:
Global Primary Hyperoxaluria Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Primary Hyperoxaluria Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Primary Hyperoxaluria Treatment companies in 2021 (%)
The global Primary Hyperoxaluria Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Primary Hyperoxaluria Treatment include Oxthera, Dicerna Pharmaceuticals, Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical, Takeda Pharmaceuticals and Wuxi Further Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Primary Hyperoxaluria Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Primary Hyperoxaluria Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Primary Hyperoxaluria Treatment Market Segment Percentages, by Type, 2021 (%)
Oral
Intravenous
Others
Global Primary Hyperoxaluria Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Primary Hyperoxaluria Treatment Market Segment Percentages, by Application, 2021 (%)
Type 1
Type 2
Type 3
Global Primary Hyperoxaluria Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Primary Hyperoxaluria Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Primary Hyperoxaluria Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Primary Hyperoxaluria Treatment revenues share in global market, 2021 (%)
Key companies Primary Hyperoxaluria Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Primary Hyperoxaluria Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Oxthera
Dicerna Pharmaceuticals
Allena Pharmaceuticals
Biocodex
Alnylam Pharmaceuticals
Tecoland Corporation
Zhejiang Tianxin Pharmaceutical
Takeda Pharmaceuticals
Wuxi Further Pharmaceutical